All News
#ACR BEST Abstracts from San Diego – Day 1
The RheumNow faculty reporters have been scouring the meeting for what they believe to be the best presentations from the first day at ACR 2023 in San Diego. From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from Sunday Nov. 12th. You can spot these on Twitter by looking for the (#ACRbest) hashtag.
Read Article
ABS0122 at #ACR23
⭐️Risk of acute MI, stroke & death signif ⬆️ among RA/SLE pts w/ depress, anxiety, &/or PTSD vs w/o both RA/SLE
➡️U.S. pts: 3825 RA, 1862 SLE --> 1790 w/ above mental health dz, no prior CVD
➡️HR 1.28 after adjusting for🚬, obesity, & comorbidities
@RheumNow https://t.co/sXMFtaKmYB
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
ABS0155 @ #ACR23
Economic impact of switching from SQ MTX (Rasuvo) from oral MTX in U.S. RA pts?'
➡️ Rasuvo associated with significantly higher all cause total expenditure $4704 predominantly due to higher costs associated tin all cause pharmacy utilization $4,223!
@Rheumnow https://t.co/ry8XxjvHRg
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
ABS0164 @ #ACR23
Is a virtual MSK test consistent & comparable to in-person assessments w/ regard to dz activity in f/u of RA pts?
YES!
Some variability in # of swollen joints but approach shown below had good reliability & acceptable lvl of agreement
@RheumNow #ACRBEST https://t.co/yxpPb2Br4n
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
TM01 @ #ACR23: Daunting Case of Diarrhea
65 yo F w/ sero+RA + 2ndary SjS p/w 4 wks diarrhea
-CT a/p: thickening of cecum, ascending colon
-Colonoscopy path: ischemia
-R colectomy: enterocoelic lymphocytic phlebitis, no underlying vasculitis. Dx: IgG4-RD, serum IgG4⬆️
@RheumNow https://t.co/jQ57U5EjPo
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
1-Can we prevent RA ? Vagotomy?
2-CV events in auto immune rheumatic disease pregnancies.
3-CVS vasculitis , challenges and role of Brain biopsy
And others……..
https://t.co/BX8bDSX1M3
@RheumNow , daily recap
#ACR23
Nouf Al hemmadi ( View Tweet)
20 years real-world data on disease burden, patient experience & unmet needs in Refractory #RheumatoidArthritis
▶️Higher glucocorticoid & opioid use
▶️Greater comorbidity & symptom burden
▶️More rheumatology visits
#ACR23
👉🏽https://t.co/CAUorjQbvN
by @KristinWipfler @Dr_K et al https://t.co/vx1aOZizfE
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
OMG! The #Gerirheum community is looking into this bias— pls fill out their survey @UnaMakris @SattuiSEMD https://t.co/Axaoo3WohH
TheDaoIndex KDAO2011 ( View Tweet)
Automated #deeplearning systems #ArtificialIntelligence identify & predict joint damage in hand radiographs from #RheumatoidArthritis patients
➡️May aid in monitoring joint damage
#ACR23
👉🏽https://t.co/IcoZHY6lns https://t.co/mZWg6YIUp3
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
ABS0433:
⭐️Older adults w/ RA less likely to receive tx w/ DMARDs despite being well tolerated and effective
➡️Retrospect, obs using Medicare data
➡️At least 66 yo old w/ new dx of late-onset RA (LORA)
🚩If no contraindications, start DMARDs early in LORA!
#ACR23 @RheumNow https://t.co/ChalcgtS2O
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Super interesting study re: impact of ORAL SURVEILLANCE on prescribing
Post safety report, JAK pts shifted younger w/lower comorbidities (esp CVD)
I know many have mixed feelings, but I believe in the risk & support this type of shift
@RheumNow Abstr0435 #ACR23 https://t.co/EBg9VOIbj1
Mike Putman EBRheum ( View Tweet)
ABS0450
⭐️Baricitinib non-inferior as well as superior to TNFi in terms of ACR50 response @ 12w in real world csDMARD refractory RA patients
➡️open-label, T2T w/ Baricitinib (n=102) vs TNFi (n=97)
➡️DAS28-CRP remission (<0.6) in 74% of Bari vs 47% of TNFi
#ACR23 @RheumNow https://t.co/yydS20hNzM
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
ARDs increase risk for CVE in pregnancy, the highest being APS, SLE (with LN and APS) and RA. Close monitoring not only during but also after pregnancy is required. #Plenary #ACR23 https://t.co/W3CSjccSno
Adela Castro AdelaCastro222 ( View Tweet)
Phase 2 RCT of TLL-018 (JAK1/TYK2i) vs Tofa in RA. 101 patients. ACR50 72% vs 42%. 83% of tofa-IR achieved ACR50 on TLL-018. Can't wait for the phase 3 data! Abstr#0840 #ACR23 @RheumNow #ACRbest https://t.co/wjGx4Edxyb https://t.co/n6CL8G01Wo
Richard Conway ( View Tweet)
Finger fold index (FFI) calculated by deep neural network model reliable for metrical analysis and detection of swelling in RA with 91% accuracy. Mean FFI significantly higher in RA vs healthy controls PIP joints @marcblanchard23 Abst#0402 #ACR23 @RheumNow https://t.co/jmPvwzf2m8 https://t.co/DOZoV0xSsd
Dr. Antoni Chan ( View Tweet)
TLL-018, the dual JAK1/Tyk2 inhibitor which caused all the chatter at #EULAR2023, now with more full data showing it absolutely smash tofacitinib in RA, with similar safety.
“This is a spectacular compound - unbelievably spectacular” - Roy Fleischmann
#ACR23 ABST0840 @RheumNow https://t.co/nIKQb4yYrJ
David Liew drdavidliew ( View Tweet)
More on TLL-018
How?
A: Everyone surprised. But maybe dual mech benefits re: pain via IFN
Where’s the multinational RCT in RA?
A: Priority on rapid registration in China, quickly. But ph2 trials for psoriasis happening in US, results so far look consistent.
#ACR23 @RheumNow
David Liew drdavidliew ( View Tweet)
What if we deliver TNFi to the wrong place?
Delivery of ETA to peripheral lymphatics instead of subcut through a wearable device in 10pts showed:
1- is Safe
2-Reduces DAS28 (but more TJC than SJC)
To be confirmed in larger and controlled study!
@RheumNow #ACR23 ABST0838 https://t.co/IUPpFwjjbj
Aurelie Najm ( View Tweet)
Taylor et al. Positive phase 2 RCT of Nipocalimab (neonatal Fc receptor blocking monoclonal) in RA. Abstr#0839 #ACR23 @RheumNow https://t.co/UHjti200yh https://t.co/tkSlLMIl7X
Richard Conway ( View Tweet)
Ph2a Nipocalumab: FcRn blocker
IV15mg/kg TNF IR RA 32 pts
Delta DASCRP -1 vs -0.5 PBO
ACR50 20% vs 0 PBO
DAS Remission 40% vs 16% Only in ACPA+ pts
SAEs 1 infusion related reaction
Not extremely convincing alone
Currently studied in combination w/ TNFi
@RheumNow #ACR23 ABST0839 https://t.co/6wTu2ellhN
Aurelie Najm ( View Tweet)